trans-Pralsetinib

• CAT Number: I018495
• CAS Number: 2097132-93-7
• Molecular Formula: C27H32FN9O2
• Molecular Weight: 533.60
• Purity: ≥95%
• Synonyms: N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide
• InChI: InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19?,27?/m0/s1
• InChIKey: GBLBJPZSROAGMF-SIYOEGHHSA-N
• SMILES: CC1=CC(=NN1)NC2=NC(=NC(=C2)C)C3CCC(CC3)(C(=O)N[C@@H](C)C4=CN=C(C=C4)N5C=C(C=N5)F)OC

trans-Pralsetinib（Cat No.:I018495）is a selective RET (rearranged during transfection) kinase inhibitor with the molecular formula C27H32FN9O2, developed for the treatment of RET-altered cancers, including non-small cell lung cancer (NSCLC) and thyroid cancers. It works by binding to the ATP-binding site of the RET kinase domain, inhibiting its signaling and downstream oncogenic pathways. The “trans” configuration refers to its stereochemistry, crucial for its biological activity and selectivity. Administered orally, trans-Pralsetinib shows efficacy in tumors with RET fusions or mutations. Common side effects include hypertension, constipation, fatigue, and liver enzyme elevation, requiring periodic monitoring.